Drugs / LY3541860
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT05042310 | Nov 2021 → Dec 2023 | — | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 22 trials | ||||||
| Phase 2 | NCT06859294 | Mar → Nov 2025 | rheumatoid arthritis | Eli Lilly and Company | Terminated | No outcome recorded |
| Phase 2 | NCT06220669 | Mar 2024 → Oct 2025 overdue | multiple sclerosis | Eli Lilly and Company | Active not recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | LY3541860 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05042310 ↗ |
| Route | Intravenous | “Administered either IV or SC.” NCT05042310 ↗ |
| Route | Subcutaneous | “Administered either IV or SC.” NCT05042310 ↗ |